Biolife Solutions' Chief Human Resources Officer Aebersold Sarah sells 714 shares at $25.61/share.
PorAinvest
miércoles, 17 de septiembre de 2025, 5:48 pm ET1 min de lectura
BLFS--
The transactions saw Mathew Aby selling 630 shares at $26.83 per share, totaling $16,902. Foster sold 511 shares at the same price, totaling $13,710. Wichterman sold 1,032 shares at $26.83 per share, totaling $27,688. These sales reduced their respective shareholdings but did not significantly impact their overall ownership percentages [1].
On September 15, 2025, Chief Human Resources Officer Sarah Aebersold sold 714 shares at a price of $25.61 per share, totaling $18,215. This sale was also conducted under a pre-established Rule 10b5-1(c) trading plan [1].
These transactions provide insights into the executives' long-term commitment to the company and their confidence in Biolife Solutions' future prospects. However, they also highlight the potential for significant changes in the executive team's ownership structure.
Biolife Solutions Inc. (BLFS) has announced that Chief Human Resources Officer Sarah Aebersold has sold 714 shares at a price of $25.61 per share on September 15, 2025.
Biolife Solutions Inc. (BLFS) has experienced significant executive share sales recently, with key officers selling a notable portion of their holdings. On September 11, 2025, Chief Scientific Officer Mathew Aby sold 630 shares, Chief Quality and Operations Officer Karen Foster sold 511 shares, and Chief Financial Officer Troy Wichterman sold 1,032 shares, all under a pre-established Rule 10b5-1(c) trading plan [1].The transactions saw Mathew Aby selling 630 shares at $26.83 per share, totaling $16,902. Foster sold 511 shares at the same price, totaling $13,710. Wichterman sold 1,032 shares at $26.83 per share, totaling $27,688. These sales reduced their respective shareholdings but did not significantly impact their overall ownership percentages [1].
On September 15, 2025, Chief Human Resources Officer Sarah Aebersold sold 714 shares at a price of $25.61 per share, totaling $18,215. This sale was also conducted under a pre-established Rule 10b5-1(c) trading plan [1].
These transactions provide insights into the executives' long-term commitment to the company and their confidence in Biolife Solutions' future prospects. However, they also highlight the potential for significant changes in the executive team's ownership structure.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios